A pharmacy-benefit change is not a treatment instruction. Medi-Cal Rx is changing which GLP-1 prescriptions it will cover for weight-loss use, while the clinical decision about whether to continue, change, or replace a medication remains with the prescriber.
Quick Answer
Starting January 1, 2026, Medi-Cal Rx will no longer cover the listed GLP-1 drugs when they are used for weight loss or weight-loss-related indications for most members. Previously approved weight-loss prior authorizations for Wegovy, Zepbound, and Saxenda end December 31, 2025. Other GLP-1 drugs can continue to follow separate coverage pathways for type 2 diabetes or other documented uses. Members younger than 21 may have a limited EPSDT prior-authorization pathway for weight-loss use. Before year-end, confirm the exact drug, documented use, authorization status, refill date, and prescriber plan. Do not stop or change the medication solely because the benefit is changing.
What Changes With Medi-Cal Rx on January 1, 2026
Medi-Cal Rx’s December 1, 2025 notice gave pharmacies and prescribers a 30-day reminder that state-budget changes would take effect at the start of the year. One of the largest patient-facing changes involves GLP-1 drugs used for weight loss.
The policy does not create one identical claim result for all ten listed drugs. Medi-Cal Rx separated the products into different coverage groups, which is why the exact medication and the documented reason for use both matter.
- December 1, 2025
- Medi-Cal Rx published the 30-day countdown.
- December 31, 2025
- Previously approved weight-loss PAs for Wegovy, Zepbound and Saxenda end.
- January 1, 2026
- The new GLP-1 weight-loss coverage policy begins.
- What does not change
- Patients should not alter treatment simply because a pharmacy benefit changes.
Coverage Is Not Treatment
How the GLP-1 Coverage Groups Differ
Medi-Cal Rx’s November and December 2025 materials divide the affected GLP-1 drugs into two practical groups.
- Wegovy, Zepbound and Saxenda
- Removed from the Contract Drugs List for weight-loss coverage. Previously approved weight-loss PAs end December 31.
- Seven other GLP-1 drugs
- Continue under type 2 diabetes diagnosis restrictions, but are no longer eligible for weight-loss use.
- Some other documented uses
- Certain non-weight-loss uses may be considered under Medi-Cal Rx rules and medical-necessity review.
- Members younger than 21
- A limited EPSDT pathway remains when a PA is submitted and approved.
Check a coverage path
Weight-loss use
Type 2 diabetes
Member younger than 21
It is compounded
Why the Documented Reason for the Prescription Matters
The same medication name can follow a different coverage pathway depending on why it is prescribed. That means “Is this drug covered?” is often less useful than “How is this drug being used, and what documentation does Medi-Cal Rx require for that use?”
For Ozempic, Rybelsus, Mounjaro, Victoza, Byetta, Bydureon and Trulicity, Medi-Cal Rx continued type 2 diabetes diagnosis restrictions. Requests for other non-weight-loss uses may be reviewed for coverage consideration based on medical necessity.
Medi-Cal Rx also described limited case-by-case consideration for Wegovy in certain non-weight-loss clinical uses and for Zepbound in obstructive sleep apnea. These are coverage-policy pathways, not instructions for patients to change why or how a medication is being used.
Do Not Redesign the Prescription to Fit Coverage
Six Questions to Discuss Before December 31
01. What is the documented reason this GLP-1 drug is being prescribed?
02. Does my current prior authorization end on December 31?
03. Will a new PA or diagnosis information be needed for the January refill?
04. If weight-loss coverage is ending, what treatment plan does my prescriber recommend?
05. Who will submit any required coverage information to Medi-Cal Rx?
06. What should happen before my current supply runs out?
Separate the Pharmacy Question From the Treatment Question
Fireside Pharmacy can help with refill timing, claim messages, prior-authorization status, pickup, transfer, and delivery. Treatment changes should be discussed with your prescriber.
What if Medi-Cal Rx Denies Coverage?
Medi-Cal Rx member information states that members who receive a Notice of Action denying GLP-1 coverage have the right to request a State Hearing. The notice includes the instructions and timing for the appeal.
Members generally have 90 days from the date of the Notice of Action to request a State Hearing. Medi-Cal Rx also describes a shorter 10-day timing rule that can matter for certain members who were already taking a GLP-1 drug and want continued coverage while the hearing is pending.
Read the Notice Promptly
For Medi-Cal Rx benefit questions, the Customer Service Center is available at 1-800-977-2273.
What to Check Before the January Refill
A short year-end review can prevent a January coverage change from becoming an avoidable medication gap.
01. Confirm the exact GLP-1 medication and strength on your pharmacy label.
02. Confirm the documented reason the prescription is being used.
03. Check whether a current prior authorization ends December 31.
04. Count how much medication remains and note the next refill date.
05. Contact the prescriber about the January plan before the current supply is nearly gone.
06. Know who to call if the January claim is denied or requires additional information.
Frequently Asked Questions
Does Medi-Cal Rx stop covering every GLP-1 drug on January 1, 2026?
No. The January policy removes coverage for the listed GLP-1 drugs when they are used for weight loss or weight-loss-related indications for most members. Some other documented uses follow different coverage pathways.
Which weight-loss prior authorizations end December 31, 2025?
Medi-Cal Rx states that previously approved weight-loss prior authorizations for Wegovy, Zepbound and Saxenda end December 31, 2025.
Can GLP-1 drugs still be covered for type 2 diabetes?
Ozempic, Rybelsus, Mounjaro, Victoza, Byetta, Bydureon and Trulicity continue under Medi-Cal Rx type 2 diabetes diagnosis restrictions, subject to the program’s claim and approval requirements.
Is there a pathway for Medi-Cal members younger than 21?
Yes. Medi-Cal Rx states that members younger than 21 may have a weight-loss coverage pathway when a PA is submitted and approved under federal EPSDT requirements.
Should I stop my GLP-1 medication if weight-loss coverage ends?
No. A pharmacy-benefit change is not a treatment instruction. Contact the prescriber managing your care before stopping, changing, or replacing the medication.
Have a January GLP-1 Coverage Question?
Use the form above to request a call about refill timing, a claim message, prior authorization, transfer, pickup, or delivery.
